These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36088167)

  • 1. Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.
    Cox S; Powell C; Morgan S
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):716-723. PubMed ID: 36088167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
    Navani N; Butler R; Ibrahimo S; Verma A; Evans M; Doherty GJ; Ahmed S
    Lung Cancer; 2022 Oct; 172():142-153. PubMed ID: 36099709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
    Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
    Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.
    Finall A; Davies G; Jones T; Emlyn G; Huey P; Mullard A
    J Clin Pathol; 2023 Jun; 76(6):391-399. PubMed ID: 35042754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
    Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
    Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
    PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.
    Penault-Llorca F; Kerr KM; Garrido P; Thunnissen E; Dequeker E; Normanno N; Patton SJ; Fairley J; Kapp J; de Ridder D; Ryška A; Moch H
    Virchows Arch; 2022 Sep; 481(3):351-366. PubMed ID: 35857103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
    Kerr KM; Bibeau F; Thunnissen E; Botling J; Ryška A; Wolf J; Öhrling K; Burdon P; Malapelle U; Büttner R
    Lung Cancer; 2021 Apr; 154():161-175. PubMed ID: 33690091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.
    Malapelle U; Donne AD; Pagni F; Fraggetta F; Rocco EG; Pasello G; Perrone G; Pepe F; Vatrano S; Pignata S; Pinto C; Pruneri G; Russo A; Soto Parra HJ; Vallone S; Marchetti A; Troncone G; Novello S
    Crit Rev Oncol Hematol; 2024 Jan; 193():104217. PubMed ID: 38040072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
    Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
    Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
    Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
    Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
    Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
    Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
    J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital.
    Burns L; Jani C; Radwan A; Omari OA; Patel M; Oxnard GR; Tapan U
    Clin Lung Cancer; 2023 Mar; 24(2):e69-e77. PubMed ID: 36464575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.